Venclexta Out Of The Starting Gate With Approval In High-Risk CLL Subset
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche/Abbvie’s first-in-class breakthrough BCL-2 inhibitor granted accelerated approval by FDA in relapsed CLL with 17p deletion.
You may also be interested in...
Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
Roche/AbbVie Move Beyond GDC-0199 Toxicity Issue To Show Results In Tough-To-Treat CLL
Small molecule Bcl-2 inhibitor GDC-0199/ABT-199 demonstrates an 84% overall response rate and a 23% complete response in early study of high risk CLL presented at ASH. However, tumor lysis syndrome caused one sudden death in the trial and is a potential risk that needs to be well-managed going forward. Roche also reports updated results of Gazyva vs. Rituxan in CLL.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.